choosing medicines in sulfonamide hypersensitivity

Choosing Medicines in Sulfonamide Hypersensitivity

Overview

• Target group:
  • patients presenting with documented sulfonamide hypersensitivity requiring treatment with antibiotic or non-antibiotic drugs
• Core clinical problem:
  • avoiding all sulfonamide-containing drugs in hypersensitive individuals can lead to suboptimal therapy or the use of less effective, more toxic alternatives
  • cross-reactivity between antibiotic sulfonamides is well established, whereas true cross-reactivity between antibiotic and non-antibiotic sulfonamides is structurally and immunologically unlikely

UK-Licensed Sulfonamide Drugs

• Sulfonamide antibiotics:
  • sulfamethoxazole (in co-trimoxazole),
  • sulfadiazine, and
  • sulfapyridine (a component of sulfasalazine)
• Non-antibiotic sulfonamide classes (all members):
  • carbonic anhydrase inhibitors,
  • loop diuretics,
  • sulfonylureas,
  • thiazide/thiazide-like diuretics
• Individual non-antibiotic sulfonamides:
  • antivirals: fosamprenavir, darunavir
  • braf inhibitors: dabrafenib, encorafenib, vemurafenib
  • cox-2 inhibitors: celecoxib, parecoxib
  • triptans: almotriptan, naratriptan, sumatriptan
  • others: rosuvastatin, sotalol, tamsulosin, topiramate, zonisamide, and sulfasalazine

Structural Basis & Mechanisms of Hypersensitivity

• Structural differences:
  • antibiotic sulfonamides possess an arylamine group at N4 and a heterocyclic aromatic ring at N1
  • non-antibiotic sulfonamides almost universally lack both the N4 arylamine group and the N1 heterocyclic ring
• Type I (immediate IgE-mediated) reactions:
  • encompass urticaria, angioedema, hypotension, and anaphylaxis
  • driven specifically by the N4 arylamine and N1 heterocyclic ring structural moieties
• Types II–IV (delayed/T-cell-mediated) reactions:
  • driven by reactive drug metabolites (nitrososulfonamides via N4 hydroxylation) binding to T-lymphocytes or proteins
  • type IV non-urticarial maculopapular rashes are the most common
  • severe cutaneous adverse reactions (SCARs) include Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and DRESS

Cross-Reactivity Profile

• Between antibiotic sulfonamides:
  • high risk of cross-reactivity due to shared N1 and N4 structural determinants
  • all other sulfonamide antibiotics must be avoided
• Between antibiotic and non-antibiotic sulfonamides:
  • cross-reactivity is not expected due to distinct chemical structures
  • historical case reports alleging cross-reactivity do not demonstrate true immune cross-reactivity
• Between non-antibiotic sulfonamides:
  • no evidence of cross-reactivity between different classes of non-antibiotic sulfonamides

Prescribing Recommendations (1):

• Sulfonamide antibiotics:
  • completely avoid in patients with a history of sulfonamide antibiotic allergy
  • desensitization or challenge testing may be considered if essential
• Sulfonamide non-antibiotics:
  • minor prior reactions (e.g., mild delayed rash/pruritus without systemic signs): can safely prescribe non-antibiotic sulfonamides if clinically indicated
  • serious prior reactions (e.g., anaphylaxis, SJS/TEN, DRESS, organ involvement): use non-sulfonamide alternatives where available; if no alternative exists, prescribe with caution following off-label/unlicensed prescribing protocols
  • prior reaction to a non-antibiotic sulfonamide: does not preclude the use of antibiotic sulfonamides or non-antibiotic sulfonamides from a different chemical class

Drugs Needing Special Consideration

• Darunavir & fosamprenavir:
  • contain an N4 arylamine group
  • caution is advised; avoid in patients with a history of serious sulfonamide antibiotic reactions if possible
• Dapsone:
  • a sulfone (not a sulfonamide) containing an N4 arylamine
  • up to 20% of sulfonamide-allergic individuals cross-react
  • avoid after serious sulfonamide reactions
• BRAF inhibitors (dabrafenib, encorafenib, vemurafenib):
  • associated with SCARs (SJS/TEN) and potential lymphocyte cross-reactivity in vitro
  • use with heightened clinical caution
• Trimethoprim:
  • non-sulfonamide co-formulated with sulfamethoxazole in co-trimoxazole
  • patients with severe co-trimoxazole reactions should also avoid trimethoprim unless tolerance is confirmed

Distinguishing Sulphur, Sulphites, and Sulphates

• Elemental sulphur
  • an essential physiological element
  • true allergy does not exist
• Sulphites
  • preservatives/antioxidants causing contact dermatitis or immediate hypersensitivity
  • no cross-reactivity with sulfonamides
• Sulphates
  • salts of sulphuric acid
  • completely unrelated to sulfonamides or sulphites with no allergenicity

Reference:

1. NHS Specialist Pharmacy Service (September 2026). Choosing medicines in sulfonamide hypersensitivity.